Key points are not available for this paper at this time.
Introduction 13. Conclusion: In clinical trials with agents that failed to prevent progression to stage 3 T1D (e.g., abatacept and oral insulin), higher T1D GRS (reflecting higher genetic burden of T1D risk) was associated with higher risk of progression, as expected. However, teplizumab modified the relationship between GRS2 and T1D risk suggesting a greater beneficial therapeutic effect in participants with T1D GRS2 ≥13. In contrast, participants with lower T1D GRS2 had worse response to teplizumab. These results support that genetics can help select individuals who will respond to treatments to prevent T1D. Disclosure M.J. Redondo: None. B.N. Bundy: None. H.M. Parikh: None. L. You: None. T.M. Triolo: None. L.A. Ferrat: Consultant; Johnson IM Therapeutics. Research Support; Imcyse. Advisory Panel; Imcyse. Consultant; Juvenile Diabetes Research Foundation (JDRF). Research Support; Hemsley Charitable Trust, Novartis AG, Provention Bio, Inc., Precigen, Inc. Advisory Panel; ViaCyte, Inc. Research Support; Nova Pharmaceuticals. S. Onengut-Gumuscu: None. S.S. Rich: None. R.A. Oram: Research Support; Randox R Provention Bio, Inc., Sanofi. K.C. Herold: Consultant; Sanofi. J. Krischer: None. Funding National Institutes of Health NIDDK 1R01DK121843
Redondo et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: